Biotech Values

[mcbio]

In AASLD data presented by Dr. Jacobson showed that patients with the Q80K polymorphism in cohort 1 had an SVR12 of 89% compared with 100% of those without Q80K. In cohort 2, this subgroup had SVR4=91% compared with 100% of those without Q80K. So, not bad at all but still patients with Q80K didn't do as good as those without it.

Thanks. Still very good data from the combo. If insurers will indeed broadly cover the combo given labeling, and that of course remains to be seen, it's hard for me to see the incentive for patients to wait for future all-oral combos to be formally approved. Not going to get leaps and bounds additional efficacy or safety or convenience for that matter (2 pills taken just once/day) than sofosbuvir + simeprevir combo.